RAIN Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 17.40%
Insider Buying (Last 12 Months): $150,040.47
Insider Selling (Last 12 Months): $0.00

Rain Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at Rain Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Rain Oncology Share Price & Price History

Current Price: $3.57
Price Change: Price Increase of +0.24 (7.21%)
As of 04/29/2025 01:00 AM ET

This chart shows the closing price history over time for RAIN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Rain Oncology (NASDAQ:RAIN)

25.79% of Rain Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RAIN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal InflowsTotal Outflows
Rain Oncology logo
As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.
Read More on Rain Oncology

Today's Range

Now: $3.57
Low: $3.18
High: $3.90

50 Day Range

MA: $1.21
Low: $1.20
High: $1.24

52 Week Range

Now: $3.57
Low: $0.82
High: $11.32

Volume

113,185 shs

Average Volume

32,376 shs

Market Capitalization

$19.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Rain Oncology?

Rain Oncology's top insider shareholders include:
  1. Kevin C Tang (Major Shareholder)
  2. Boxer Capital, Llc (Insider)
  3. Paul T Dacier (Major Shareholder)
Learn More about top insider investors at Rain Oncology.